Visit Nektar Therapeutics

We’re gearing up for #SITC22 this year, where Nektar is presenting data including the first preclinical findings from our research program, NKTR-288, a novel interferon gamma mutein. Click here to learn more: https://t.co/zlopTmomxN https://t.co/DJCIHimIeY

On #WorldCancerResearchDay, we thank our patients & team of dedicated scientists and clinicians for continuing in the fight against cancer. Learn how IL-15 agonist NKTR-255 is designed to boost the immune system’s natural ability to fight cancer: https://t.co/Tm25giOCIq https://t.co/zM2Lths93I

This #BloodCancerAwarenessMonth, we’re evaluating a novel IL-15 agonist NKTR-255 as a potential treatment for patients with #multiplemyeloma, #nonHodgkinlymphoma and #DLBCL. Together we can #CancelBloodCancer. Learn more: https://t.co/zPoCrgL3LW https://t.co/hF1FvTOrGi

Thank you @eadv & our presenters for a great #EADVCongress! We’re excited about the potential of NKTR-358 to address the imbalance in the immune system that causes autoimmune disorders & chronic inflammatory conditions. Explore our posters: https://t.co/JzIoe6gvLx https://t.co/2M1etIXl2z

Christie Fanton, Ph.D., our VP of Translational Medicine published an article discussing her thoughts on the current treatment landscape in AD & why REZPEG could be the key to restoring balance in the immune system to treat the disease. Full article here: https://t.co/nuVo1yIico

We’re looking forward to the #EADVCongress kicking off today, where we’re presenting Phase 1b data for REZPEG (NKTR-358) in Atopic Dermatitis and Psoriasis. Click here for our full data press release: https://t.co/HRalnR5dKp https://t.co/uP6SouShHk

It’s #AutoimmuneDiseaseAwarenessMonth. Dedicated to developing novel therapies for patients affected by #autoimmunediseases, we are evaluating NKTR-358, our investigational therapeutic candidate, in multiple trials. Learn more: https://t.co/DlOZpO7aap https://t.co/Dm6frUMwDk

This #InternationalWomensDay, we’re saying thank you to all the women on our team developing innovative #immunotherapy treatments! Nektar is also proud to work with organizations supporting the advancement of #WomeninSTEM. #IWD2022 https://t.co/2ifQLW8b9v

In honor of #EmployeeAppreciationDay, we’re celebrating and expressing gratitude for our team! Thanks for your dedication to patients as we advance potential #immunotherapies and for making Nektar a rewarding place to work. Learn more about us: https://t.co/7r76hKbB6Y https://t.co/YqH85HrWIe

We had a great time today at the @SFBusinessTimes #SFBTwomenwholead event and the privilege of hearing from female #biotech leaders. At Nektar, we believe in the importance of promoting opportunities for #womeninSTEM. Hear more from our colleague Wildaliz Nieves, Ph.D. https://t.co/yvv0KIQdvY

We’re pleased to advance investigation of BEMPEG as a treatment for #genitourinary #cancers and join @ASCO #GU22 to highlight our clinical trials in urothelial carcinoma and in renal cell carcinoma. Learn more about our IL-2 #immunotherapy: https://t.co/slOmoYlgle https://t.co/5P7iQlE3YE

Proud partners of the organization, we’re featuring @WomenInBio during #IDWGS 2022. Offering career support, mentorship and training for women in #biotech, they’ve created a diverse and inclusive community of #womeninSTEM. Read more: https://t.co/qKISLuiFCs https://t.co/iQbI7zBADp

This International Day of Women and Girls in Science #IDWGS, we’re celebrating @NexGeneGirls, an organization providing opportunities and mentorship in our local communities. Together, we are empowering the next generation of #girlsinSTEM. Learn more: https://t.co/KzElLDzGYJ https://t.co/clIiGIsevn

Today is #WorldCancerDay. Our team is privileged to work at the cutting edge of science and #oncology to create potential new #cancer therapies for people impacted by these debilitating diseases. Learn about our commitment: https://t.co/JSKX3jSoos https://t.co/LJgYBJphU9

We’re pleased to share a new manuscript in @futuresciencegp on the currently enrolling PIVOT-12 Phase 3 study evaluating BEMPEG (NKTR-214) for adjuvant use in patients with resected #melanoma. Read here: https://t.co/osJsS8jV4A

It’s #NationalMentoringMonth, and we’re celebrating the valuable impact mentors have in #biotech and #STEM. Our team is proud to support the next generation, which you can read about here: https://t.co/Cu0Y8Yn4xV https://t.co/oaUJPli70Y

At #JPM2022 next week, Company management will present on the exciting advances we are making across our #immunooncology and #immunotherapy pipelines. Learn more about our programs: https://t.co/zPoCrgKvWo https://t.co/32GqRiwHV3

We’re excited about the potential of our NKTR-358 program in partnership with @LillyPad to treat #autoimmune disorders and restore the immune system balance with T regulatory cells. Learn more about this first-in-class IL-2 agonist: https://t.co/DlOZpO7aap https://t.co/NFK75cJOPy

Today, our partner @LillyPad presented encouraging new data from a Phase 1b study of our novel T regulatory cell stimulator, NKTR-358, in patients with #atopicdermatitis. Read about these findings’ potential for treating #autoimmune disorders: https://t.co/jBjG0nI3WR https://t.co/TmiXBZCS70

At #ASH21, we presented data for NKTR-255 in patients with hematologic malignancies, including patients with prior CAR-T Therapy. Learn more: https://t.co/fgiLXXHH7z #immunooncology #cancer https://t.co/TCQuTPRTwI